JAK2 and myeloid leukemia: While evaluating the therapeutic relevance of CARM1 inhibition, we observed the differential sensitivity of AML cell lines and noticed that JAK2-V617F mutation-positive myeloid leukemia cells showed a lower sensitivity to CARM1-inhibition24.